Form 8-K BRUKER CORP For: Feb 08

February 8, 2018 4:11 PM

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934

 


 

Date of Report (Date of earliest event reported): February 8, 2018

 

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction
of incorporation)

 

000-30833
(Commission
File Number)

 

04-3110160
(IRS Employer
Identification No.)

 

40 Manning Road
Billerica, MA 01821
(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code: (978) 663-3660

 

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the reporting obligation of the registrant under any of the following provisions:

 

o                Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                Soliciting material pursuant to Rule 14a-12 of the Exchange Act (17 CFR 240.14a-12)

 

o                Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 



 

Section 2 — Financial Information

 

Item 2.02.  Results of Operations and Financial Condition.

 

On February 8, 2018, Bruker Corporation issued a press release announcing combined financial results as of and for the three and twelve months ended December 31, 2017 and providing initial guidance for its 2018 fiscal year.  A copy of the press release is attached hereto as Exhibit 99.1.

 

The information in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

Cautionary Note Regarding Forward-Looking Statements

 

Except for historical information contained in the press release attached hereto as Exhibit 99.1, the press release contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those indicated by these statements.  Please refer to the cautionary note contained in the press release under the heading “Forward Looking Statements” for additional information regarding these forward-looking statements.

 

Section 9 — Financial Statements and Exhibits

 

Item 9.01.  Financial Statements and Exhibits.

 

(d)                 Exhibits.

 

Number

 

Description

 

 

 

99.1

 

Press release dated February 8, 2018.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BRUKER CORPORATION

 

(Registrant)

 

 

Date: February 8, 2018

By:

/s/Anthony L. Mattacchione

 

Anthony L. Mattacchione

 

Chief Financial Officer and

 

Senior Vice President

 

3


Exhibit 99.1

 

Bruker Reports Fourth Quarter and Fiscal Year 2017 Financial Results

 

BILLERICA, Mass.February 8, 2018 — Bruker Corporation (NASDAQ: BRKR) today announced financial results for its fourth quarter and fiscal year ended December 31, 2017.

 

Bruker’s revenues for the fourth quarter of 2017 were $530.5 million, an increase of 12.8% compared to the fourth quarter of 2016. In the fourth quarter of 2017, Bruker’s year-over-year organic revenue growth was 4.0%, while growth from acquisitions was 3.6%, and the favorable effect from changes in foreign currency rates was 5.2%.

 

Fourth quarter 2017 GAAP operating income was $93.7 million, compared to $76.9 million in the fourth quarter of 2016, and GAAP operating margin was 17.7%, versus 16.4% in the fourth quarter of 2016. Non-GAAP operating income was $110.8 million, an increase of 20% over $92.0 million in the fourth quarter of 2016. Bruker’s fourth quarter 2017 non-GAAP operating margin was 20.9%, compared to 19.6% in the fourth quarter of 2016.

 

Due to the effects of U.S. tax reform, Bruker recorded a charge of $68.9 million in the fourth quarter 2017, resulting in a GAAP loss per diluted share of ($0.02), compared to GAAP earnings per diluted share (EPS) of $0.43 in the fourth quarter of 2016. Fourth quarter 2017 non-GAAP EPS were $0.51, an increase of 11% compared to $0.46 in the fourth quarter of 2016. A reconciliation of non-GAAP to GAAP financial measures is provided in the tables accompanying this press release.

 

For the year 2017, Bruker’s revenues increased 9.6% to $1.766 billion, compared to $1.611 billion in the year 2016. In 2017, Bruker’s year-over-year organic revenue growth was 3.6%, while growth from acquisitions was 4.8%, and the favorable effect from changes in foreign currency rates was 1.2%. Bruker’s year-over-year organic revenue growth of 3.6% in 2017 consisted of organic revenue growth of 2.7% in the Bruker Scientific Instruments (BSI) segment and of 14.5% in the BEST segment, net of intercompany eliminations.

 

For the year 2017, GAAP operating income was $214.7 million, compared to $177.2 million in 2016, and GAAP operating margin was 12.2%, versus 11.0% in 2016. Non-GAAP operating income was $276.1 million in 2017, an increase of 16% over non-GAAP operating income of $237.9 million in 2016. Bruker’s 2017 non-GAAP operating margin was 15.6%, compared to 14.8% in 2016.

 

Fiscal year 2017 GAAP diluted EPS were $0.49, compared to $0.95 in 2016. The decrease was primarily due to the effects of U.S. tax reform in the fourth quarter of 2017. Non-GAAP EPS for 2017 were $1.21, compared to $1.19 in the year 2016, which had benefitted from an unusually favorable tax rate, as previously disclosed.

 

Frank Laukien, President and CEO of Bruker, commented: “We are encouraged by our finish to the year, as Bruker exceeded our recently increased full year 2017 revenue growth and non-GAAP EPS objectives. In 2017, low-single digit year-over-year organic revenue growth returned to our core Scientific Instruments segment, whereas our BEST segment delivered mid-teens organic revenue growth. For 2018, we expect further gradual improvement in our full year Scientific Instruments organic growth rate, while BEST revenues are expected to decline in the low single digits organically year-over-year.”

 

Dr. Laukien continued: “We are also pleased that Bruker achieved 80 bps of non-GAAP operating margin expansion in 2017, even with 45 bps of acquisition headwinds and 20 bps of currency headwinds. For the full year 2018, we expect continued healthy non-GAAP operating margin expansion, despite a substantial currency headwind.”

 



 

Fiscal Year 2018 Financial Outlook

 

Bruker is providing initial revenue growth, operating margin expansion and EPS guidance for fiscal year (FY) 2018 based on average foreign exchange rates for the month of January 2018.

 

For FY 2018, the Company expects revenue growth of approximately 7%, including organic revenue growth of approximately 3%, and a foreign currency revenue tailwind of approximately 4%. The Company projects an increase in FY 2018 non-GAAP operating margin ranging from 50 basis points (bps) to 80 bps year-over-year, including an estimated 70 bps margin headwind from foreign currency translation. Finally, for FY 2018 Bruker expects non-GAAP EPS between $1.34 and $1.38, an 11% to 14% increase compared to 2017.

 

For the Company’s outlook for FY 2018 non-GAAP operating margin and non-GAAP EPS, we are not able to provide without unreasonable effort the most directly comparable GAAP financial measures, or reconciliations to such GAAP financial measures on a forward-looking basis. Please see “Use of Non-GAAP Financial Measures” below for a description of items excluded from our expected non-GAAP operating margin and non-GAAP EPS.

 

Quarterly Earnings Call

 

Bruker will host a conference call and webcast to discuss its financial results, business outlook, and related corporate and financial matters today at 4:30 p.m. Eastern Standard Time.  To listen to the webcast, investors can go to http://ir.bruker.com and click on the “Events & Presentations” hyperlink.  A slide presentation that will be referenced during the webcast will be posted to the Company’s website shortly before the webcast begins.  Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (US toll free) or +1-412-317-6702 (international), and referencing “Bruker’s Fourth Quarter and Fiscal Year 2017 Earnings Conference Call”.  A telephone replay of the conference call will be available by dialing 1-877-344-7529 (US toll free) or +1-412-317-0088 (international) and entering conference number: 10116535. The replay will be available beginning one hour after the end of the conference through March 8, 2018.

 

About Bruker Corporation

 

For more than 55 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research, microbiology and molecular pathology research. For more information, please visit: www.bruker.com.

 

Use of Non-GAAP Financial Measures

 

To supplement our consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (GAAP), we use the following non-GAAP financial measures in this press release and in the earnings webcast: non-GAAP gross profit; non-GAAP gross profit margin; non-GAAP operating income; non-GAAP operating margin; non-GAAP profit before tax; non-GAAP tax rate; non-GAAP net income and non-GAAP earnings per share. These non-GAAP measures exclude costs related to restructuring actions, acquisition and related integration expenses, amortization of acquired intangible assets, the estimated impact of US tax reform and other non-operational costs.

 

We also refer to organic revenue growth, return on invested capital and free cash flow in this press release and in the earnings webcast, which are also non-GAAP financial measures. We define the term organic revenue as GAAP revenue excluding the effect of changes in foreign currency translation rates and the effect of acquisitions and divestitures, and believe it is a useful measure to evaluate our continuing business.  We define free cash flow as net cash provided by operating activities less additions to property, plant, and equipment.  We believe free cash flow is a useful measure to evaluate our business because it indicates the amount of cash generated after additions to property, plant, and equipment that is available for, among other things, acquisitions, investments in our business, repayment of debt and return of capital to shareholders. We define return on invested capital (ROIC) as non-GAAP operating profit after income tax divided by average total capital, which we define as debt plus equity minus cash.  We believe ROIC is an important measure of how effectively the Company invests its capital.

 



 

The presentation of these non-GAAP financial measures is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP and may be different from non-GAAP financial measures used by other companies, and therefore, may not be comparable among companies.  We believe these non-GAAP financial measures provide meaningful supplemental information regarding our performance. Specifically, management believes that the non-GAAP measures mentioned above provide relevant and useful information which is widely used by analysts, investors and competitors in our industry, as well as by our management, in assessing both consolidated and business unit performance.

 

We use these non-GAAP financial measures to evaluate our period-over-period operating performance because our management believes this provides a more comparable measure of our continuing business by adjusting for certain items that are not reflective of the underlying performance of our business. These measures may also be useful to investors in evaluating the underlying operating performance of our business and forecasting future results.  We regularly use these non-GAAP financial measures internally to understand, manage, and evaluate our business results and make operating decisions.  We also measure our employees and compensate them, in part, based on such non-GAAP measures and use this information for our planning and forecasting activities.

 

Additional information relating to these non-GAAP financial measures and reconciliations to the most directly comparable GAAP financial measures is provided in the tables accompanying this press release following our GAAP financial statements and in our slide presentation, which is available through the “Earnings Release” hyperlink on Bruker’s Investor Relations web site ir.bruker.com.

 

With respect to the Company’s outlook for 2018 non-GAAP operating margin, non-GAAP EPS and non-GAAP tax rate, we are not providing the most directly comparable GAAP financial measures or corresponding reconciliations to such GAAP financial measures on a forward-looking basis, because we are unable to predict with reasonable certainty certain items that may affect such measures calculated and presented in accordance with GAAP without unreasonable effort. Our expected non-GAAP operating margin, tax rate and EPS ranges exclude primarily the future impact of restructuring actions, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments. These reconciling items are uncertain, depend on various factors outside our management’s control and could significantly impact, either individually or in the aggregate, our future period operating margins, EPS and tax rate calculated and presented in accordance with GAAP.

 

Forward Looking Statements

 

Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, fluctuations in foreign currency exchange rates, our ability to successfully implement our restructuring initiatives, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners, key suppliers and contract manufacturers, capital spending and government funding policies, changes in governmental regulations, the use and protection of intellectual property rights, litigation, and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2016 and subsequently filed Quarterly Reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

 

-tables follow-

 

Contacts:

Miroslava Minkova

Head of Investor Relations

Bruker Corporation

T: +1 (978) 663 — 3660, ext. 1479

E: miroslava.minkova@bruker.com

 



 

Bruker Corporation

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

 

 

 

December 31,

 

December 31,

 

(in millions)

 

2017

 

2016

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

325.0

 

$

342.4

 

Short-term investments

 

114.2

 

157.9

 

Accounts receivable, net

 

319.3

 

243.9

 

Inventories

 

486.2

 

440.4

 

Other current assets

 

114.1

 

91.3

 

Total current assets

 

1,358.8

 

1,275.9

 

 

 

 

 

 

 

Property, plant and equipment, net

 

266.5

 

239.1

 

Intangibles, net and other long-term assets

 

323.2

 

293.4

 

 

 

 

 

 

 

Total assets

 

$

1,948.5

 

$

1,808.4

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Current portion of long-term debt

 

$

 

$

20.1

 

Accounts payable

 

90.8

 

86.1

 

Customer advances

 

111.7

 

149.0

 

Other current liabilities

 

322.0

 

269.5

 

Total current liabilities

 

524.5

 

524.7

 

 

 

 

 

 

 

Long-term debt

 

415.6

 

391.6

 

Other long-term liabilities

 

274.9

 

199.0

 

 

 

 

 

 

 

Total shareholders’ equity

 

733.5

 

693.1

 

 

 

 

 

 

 

Total liabilities and shareholders’ equity

 

$

1,948.5

 

$

1,808.4

 

 

FOR FURTHER INFORMATION:

 

Miroslava Minkova, Head of Investor Relations

 

 

Tel: +1 (978) 663-3660, ext. 1479

 

 

Email: miroslava.minkova@bruker.com

 



 

Bruker Corporation

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

 

 

 

Three Months Ended

 

Twelve Months Ended

 

 

 

December 31,

 

December 31,

 

(in millions, except per share amounts)

 

2017

 

2016

 

2017

 

2016

 

Revenues

 

$

530.5

 

$

470.3

 

$

1,765.9

 

$

1,611.3

 

Cost of revenues

 

275.3

 

249.9

 

952.9

 

868.8

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

255.2

 

220.4

 

813.0

 

742.5

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

112.1

 

100.1

 

415.9

 

390.5

 

Research and development

 

43.5

 

38.2

 

162.7

 

149.0

 

Other charges, net

 

5.9

 

5.2

 

19.7

 

25.8

 

Total operating expenses

 

161.5

 

143.5

 

598.3

 

565.3

 

 

 

 

 

 

 

 

 

 

 

Operating income

 

93.7

 

76.9

 

214.7

 

177.2

 

 

 

 

 

 

 

 

 

 

 

Interest and other income (expense), net

 

(5.1

)

11.5

 

(16.9

)

0.4

 

 

 

 

 

 

 

 

 

 

 

Income before income taxes and noncontrolling interest in consolidated subsidiaries

 

88.6

 

88.4

 

197.8

 

177.6

 

Income tax provision

 

91.6

 

19.3

 

117.5

 

23.1

 

 

 

 

 

 

 

 

 

 

 

Consolidated net income (loss)

 

(3.0

)

69.1

 

80.3

 

154.5

 

Net income attributable to noncontrolling interests in consolidated subsidiaries

 

0.4

 

0.1

 

1.7

 

0.9

 

Net income (loss) attributable to Bruker Corporation

 

$

(3.4

)

$

69.0

 

$

78.6

 

$

153.6

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per common share attributable to Bruker Corporation shareholders:

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.02

)

$

0.43

 

$

0.50

 

$

0.95

 

Diluted

 

$

(0.02

)

$

0.43

 

$

0.49

 

$

0.95

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding:

 

 

 

 

 

 

 

 

 

Basic

 

155.7

 

160.1

 

158.1

 

161.4

 

Diluted

 

155.7

 

160.7

 

159.1

 

162.2

 

 



 

Bruker Corporation

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

 

 

 

Three Months Ended

 

Twelve Months Ended

 

 

 

December 31,

 

December 31,

 

(in millions)

 

2017

 

2016

 

2017

 

2016

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

Consolidated net income (loss)

 

$

(3.0

)

$

69.1

 

$

80.3

 

$

154.5

 

Adjustments to reconcile consolidated net income to cash flows from operating activities:

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

15.7

 

13.9

 

63.9

 

54.3

 

Stock-based compensation expense

 

2.6

 

2.6

 

11.0

 

9.4

 

Deferred income taxes

 

33.2

 

9.4

 

28.2

 

(22.7

)

Other non-cash expenses, net

 

5.5

 

(1.1

)

11.6

 

24.1

 

Changes in operating assets and liabilities, net of acquisitions and divestitures:

 

 

 

 

 

 

 

 

 

Accounts receivable

 

(47.1

)

(23.8

)

(55.5

)

(8.4

)

Inventories

 

30.9

 

30.2

 

(6.6

)

(43.2

)

Accounts payable and accrued expenses

 

42.3

 

(8.1

)

33.7

 

(19.6

)

Income taxes payable, net

 

11.5

 

(7.0

)

5.2

 

(26.8

)

Deferred revenue

 

4.2

 

1.9

 

4.0

 

4.9

 

Customer advances

 

6.9

 

(0.8

)

(27.8

)

(7.3

)

Other changes in operating assets and liabilities, net

 

1.0

 

4.5

 

6.4

 

11.6

 

Net cash provided by operating activities

 

103.7

 

90.8

 

154.4

 

130.8

 

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

Purchases of short-term investments

 

 

(48.9

)

(118.5

)

(126.5

)

Maturities of short-term investments

 

52.8

 

42.6

 

186.8

 

165.0

 

Cash paid for acquisitions, net of cash acquired

 

(0.5

)

(23.1

)

(66.3

)

(24.3

)

Purchases of property, plant and equipment

 

(12.4

)

(11.1

)

(43.7

)

(37.1

)

Proceeds from sales of property, plant and equipment

 

4.6

 

0.2

 

11.5

 

1.1

 

Net cash provided by (used in) investing activities

 

44.5

 

(40.3

)

(30.2

)

(21.8

)

 

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

Proceeds from revolving lines of credit

 

 

47.0

 

154.0

 

146.0

 

Repayment of revolving lines of credit

 

(65.0

)

 

(130.0

)

 

Repayment of note purchase agreement

 

 

 

(20.0

)

 

Proceeds (Repayment) of other debt, net

 

0.1

 

(0.2

)

(0.9

)

(0.1

)

Proceeds from issuance of common stock, net

 

4.7

 

1.3

 

20.0

 

11.5

 

Repurchase of common stock

 

(22.5

)

(16.5

)

(152.2

)

(160.0

)

Payment of dividends

 

(6.3

)

(6.4

)

(25.4

)

(25.8

)

Payment of contingent consideration

 

 

 

(3.5

)

 

Cash payments to noncontrolling interest

 

(0.5

)

 

(1.0

)

(0.7

)

Excess tax benefit related to stock option awards

 

 

0.9

 

 

1.2

 

Net cash (used in) provided by financing activities

 

(89.5

)

26.1

 

(159.0

)

(27.9

)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

 

2.4

 

(13.0

)

17.8

 

(6.4

)

Net change in cash, cash equivalents and restricted cash

 

61.1

 

63.6

 

(17.0

)

74.7

 

Cash, cash equivalents and restricted cash at beginning of period

 

267.8

 

282.3

 

345.9

 

271.2

 

Cash, cash equivalents and restricted cash at end of period

 

$

328.9

 

$

345.9

 

$

328.9

 

$

345.9

 

 



 

Bruker Corporation

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (unaudited)

 

 

 

Three Months Ended December 31,

 

Twelve Months Ended December 31,

 

(in millions, except per share amounts)

 

2017

 

2016

 

2017

 

2016

 

Reconciliation of Non-GAAP Operating Income, Non-GAAP Profit Before Tax, Non-GAAP Net Income, and Non-GAAP EPS

 

 

 

 

 

 

 

 

 

GAAP Operating Income

 

$

93.7

 

$

76.9

 

$

214.7

 

$

177.2

 

Non-GAAP Adjustments:

 

 

 

 

 

 

 

 

 

Restructuring Costs

 

7.7

 

8.0

 

16.2

 

20.8

 

Acquisition-Related Costs

 

0.8

 

0.7

 

10.2

 

11.1

 

Purchased Intangible Amortization

 

7.0

 

5.5

 

29.6

 

21.7

 

Other Costs

 

1.6

 

0.9

 

5.4

 

7.1

 

Total Non-GAAP Adjustments:

 

$

17.1

 

$

15.1

 

$

61.4

 

$

60.7

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP Operating Income

 

$

110.8

 

$

92.0

 

$

276.1

 

$

237.9

 

Non-GAAP Operating Margin

 

20.9

%

19.6

%

15.6

%

14.8

%

 

 

 

 

 

 

 

 

 

 

Non-GAAP Interest & Other Expense, net

 

(4.6

)

2.3

 

(17.5

)

(8.8

)

Non-GAAP Profit Before Tax

 

106.2

 

94.3

 

258.6

 

229.1

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP Income Tax Provision

 

(26.0

)

(20.5

)

(64.7

)

(35.9

)

Non-GAAP Tax Rate

 

24.5

%

21.7

%

25.0

%

15.7

%

 

 

 

 

 

 

 

 

 

 

Minority Interest

 

(0.4

)

(0.1

)

(1.7

)

(0.9

)

 

 

 

 

 

 

 

 

 

 

Non-GAAP Net Income Attributable to Bruker

 

79.8

 

73.7

 

192.2

 

192.3

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Shares Outstanding (Diluted)

 

156.9

 

160.7

 

159.1

 

162.2

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP Earnings Per Share

 

$

0.51

 

$

0.46

 

$

1.21

 

$

1.19

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of GAAP and Non-GAAP Gross Profit

 

 

 

 

 

 

 

 

 

GAAP Gross Profit

 

$

255.2

 

$

220.4

 

$

813.0

 

$

742.5

 

Non-GAAP Adjustments:

 

 

 

 

 

 

 

 

 

Restructuring Costs

 

4.0

 

4.6

 

5.6

 

11.0

 

Acquisition-Related Costs

 

0.1

 

(0.2

)

5.7

 

2.1

 

Purchased Intangible Amortization

 

5.6

 

4.7

 

24.0

 

18.7

 

Other Costs

 

0.1

 

 

0.8

 

0.1

 

Total Non-GAAP Adjustments:

 

9.8

 

9.1

 

36.1

 

31.9

 

Non-GAAP Gross Profit

 

$

265.0

 

$

229.5

 

$

849.1

 

$

774.4

 

Non-GAAP Gross Margin

 

50.0

%

48.8

%

48.1

%

48.1

%

 

 

 

 

 

 

 

 

 

 

Reconciliation of GAAP and Non-GAAP Tax Rate

 

 

 

 

 

 

 

 

 

GAAP Tax Rate

 

103.4

%

21.8

%

59.4

%

13.0

%

Non-GAAP Adjustments:

 

 

 

 

 

 

 

 

 

Tax Impact of Non-GAAP Adjustments

 

-1.6

%

-0.2

%

-0.1

%

-1.0

%

Tax Authority Settlements

 

0.0

%

0.1

%

0.0

%

0.1

%

Valuation Allowance Release

 

0.0

%

0.3

%

0.0

%

3.7

%

U.S. Tax Reform- Toll Charge

 

-62.1

%

0.0

%

-27.8

%

0.0

%

U.S. Tax Reform- Tax Rate Change

 

-1.3

%

0.0

%

-0.6

%

0.0

%

U.S. Tax Reform- Change in APB 23

 

-14.4

%

0.0

%

-6.5

%

0.0

%

Other Discrete Items

 

0.5

%

-0.3

%

0.6

%

-0.1

%

Total Non-GAAP Adjustments:

 

-78.9

%

-0.1

%

-34.4

%

2.7

%

Non-GAAP Tax Rate

 

24.5

%

21.7

%

25.0

%

15.7

%

 

 

 

 

 

 

 

 

 

 

Reconciliation of GAAP and Non-GAAP Interest & Other Income (Expense), net

 

 

 

 

 

 

 

 

 

GAAP Interest & Other Income (Expense), net

 

$

(5.1

)

$

11.5

 

$

(16.9

)

$

0.4

 

Non-GAAP Adjustments:

 

 

 

 

 

 

 

 

 

Bargain Purchase Gain

 

0.5

 

(9.2

)

(0.6

)

(9.2

)

Non-GAAP Interest & Other Income (Expense), net

 

$

(4.6

)

$

2.3

 

$

(17.5

)

$

(8.8

)

 



 

Bruker Corporation

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (unaudited)

 

 

 

Three Months Ended December 31,

 

Twelve Months Ended December 31,

 

(in millions, except per share amounts)

 

2017

 

2016

 

2017

 

2016

 

Reconciliation of Non-GAAP Operating Income, Non-GAAP Profit Before Tax, Non-GAAP Net Income, and Non-GAAP EPS

 

 

 

 

 

 

 

 

 

Reconciliation of GAAP and Non-GAAP Earnings Per Share (Diluted)

 

 

 

 

 

 

 

 

 

GAAP Earnings Per Share (Diluted)

 

$

(0.02

)

$

0.43

 

$

0.49

 

$

0.95

 

Non-GAAP Adjustments:

 

 

 

 

 

 

 

 

 

Restructuring Costs

 

0.05

 

0.05

 

0.10

 

0.13

 

Acquisition-Related Costs

 

0.01

 

0.01

 

0.06

 

0.07

 

Purchased Intangible Amortization

 

0.04

 

0.03

 

0.19

 

0.14

 

Other Costs

 

0.01

 

0.01

 

0.03

 

0.04

 

Bargain Purchase Gain

 

0.00

 

(0.06

)

 

(0.06

)

Income Tax Rate Differential

 

0.42

 

(0.01

)

0.33

 

(0.08

)

Total Non-GAAP Adjustments:

 

0.53

 

0.03

 

0.72

 

0.24

 

Non-GAAP Earnings Per Share (Diluted)

 

$

0.51

 

$

0.46

 

$

1.21

 

$

1.19

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of GAAP Operating Cash Flow and Non-GAAP Free Cash Flow

 

 

 

 

 

 

 

 

 

GAAP Operating Cash Flow

 

$

103.7

 

$

90.8

 

$

154.4

 

$

130.8

 

Non-GAAP Adjustments:

 

 

 

 

 

 

 

 

 

Purchases of property, plant and equipment

 

(12.4

)

(11.1

)

(43.7

)

(37.1

)

Non-GAAP Free Cash Flow

 

$

91.3

 

$

79.7

 

$

110.7

 

$

93.7

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of GAAP Revenue and Non-GAAP Revenue

 

 

 

 

 

 

 

 

 

GAAP Revenue as of Prior Comparable Period

 

$

470.3

 

$

478.2

 

$

1,611.3

 

$

1,623.8

 

Non-GAAP Adjustments:

 

 

 

 

 

 

 

 

 

Acquisitions and divestitures

 

16.8

 

8.9

 

77.2

 

32.4

 

Currency

 

24.6

 

(6.4

)

19.6

 

(8.3

)

Organic

 

18.8

 

(10.4

)

57.8

 

(36.6

)

Total Non-GAAP Adjustments:

 

60.2

 

(7.9

)

154.6

 

(12.5

)

Non-GAAP Revenue

 

$

530.5

 

$

470.3

 

$

1,765.9

 

$

1,611.3

 

Organic Revenue Growth

 

4.0

%

-2.2

%

3.6

%

-2.3

%

 

 

 

 

 

 

 

 

 

 

Reconciliation of Non-GAAP Return on Invested Capital (ROIC)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP Operating Income (from above)

 

$

110.8

 

$

92.0

 

$

276.1

 

$

237.9

 

Less: Non-GAAP Income Tax Provision (from above)

 

(26.0

)

(20.5

)

(64.7

)

(35.9

)

Non-GAAP Operating Income after Tax

 

$

84.8

 

$

71.5

 

$

211.4

 

$

202.0

 

 

 

 

 

 

 

 

 

 

 

Average Total Invested Capital:

 

 

 

 

 

 

 

 

 

Average Long-Term Debt

 

$

448.1

 

$

368.1

 

$

403.6

 

$

328.8

 

Average Current portion of Long-Term Debt

 

0.0

 

20.1

 

10.1

 

10.4

 

Average Total Shareholders’ Equity

 

736.7

 

697.0

 

713.3

 

713.0

 

Less: Average Cash and Cash Equivalents

 

(294.5

)

(310.5

)

(333.7

)

(304.8

)

Average Total Invested Capital

 

$

890.3

 

$

774.7

 

$

793.3

 

$

747.4

 

 

 

 

 

 

 

 

 

 

 

Return on Invested Capital (ROIC)

 

9.5

%

9.2

%

26.6

%

27.0

%

 

Days Inventory Outstanding is calculated as follows: GAAP Average Inventory balance divided by (GAAP Revenue less Non-GAAP Gross Profit (defined above))

 

Days Payable Outstanding is calculated as follows:  GAAP Average Accounts Payable balance divided by (GAAP Revenue less Non-GAAP Gross Profit (defined above) plus the Change in GAAP Inventory balance)

 

Days Sales Outstanding is calculated as follows:  GAAP Average Accounts Receivable balance divided by GAAP Revenue

 


Categories

SEC Filings

Next Articles